Market Movers, July.08

7:10am, Dow futures down 49 points

7:28am, Oasmia Pharmaceuticals AB up 26.87% on 77840 shares traded.  Looks like it’s just follow through from yesterdays rally, no apparent news

7:26am, SGMO up 15% on 32,640 shares traded after reporting “Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy”, Read more

7:28am, AYTU up 8% on 2500 shares traded after reporting, “acceptance of a new manuscript submitted to the Journal of the Endocrine Society, demonstrating that Natesto® achieves similar symptom improvement, regardless of the degree of patients’ testosterone deficiency, while maintaining function of the Hypothalamic-Pituitary-Gonadal (HPG) axis in hypogonadal men”. Read more

7:37am, CBIO up 3% on 50,460 shares traded after reporting “Subcutaneous MarzAA (FVIIa) prophylaxis reduced the annualized bleeding rate by more than 90% compared with pretreatment”, Read more
It has been hot of over the past few days. Looks like there was a block trade right before it took off too.

courtesy tradingview

7:51am, Symantec up 4.88% on 130,886 shares traded after “Jefferies analyst John DiFucci raised his price target for Symantec (SYMC) to $24 from $19”, reports

AVGR looked great for a swing trade on Friday, up 6.7% as of 8:24am on 74900 shares traded.

courtesy tradingview

8:30am CannTrust Holdings Inc down 19% on 395,437 shares traded after reporting their greenhouse facility in Pelham, Ontario was non-compliant with certain Health Canada regulations.
“The non-compliant rating is based on observations by the regulator regarding the growing of cannabis in five unlicensed rooms and inaccurate information provided to the regulator by CannTrust employees”.  Read more

8:37am, Intra-Cellular Therapies down 14% on 890,776 shares traded after reporting disappointing results in their phase 3 trials for Lumateperone in patients with bipolar depression.  “In Study 401, lumateperone did not separate from placebo. A high placebo response was observed in the trial”.  Read more

9:01am Adma Biologics up 4% on 54,552 shares traded after reporting “the United States Food and Drug Administration has notified ADMA the licenses for BIVIGAM and Nabi-HB have been revoked from Biotest Pharmaceuticals Corporation,  and transferred and issued to ADMA”.  Read more

Quote, “BlackRock sees economic outlook worsening for the second half, but stocks doing well anyway”, CNBC reports

Dow open 100 points lower, Apple down 1.5%.

“Soliton to Announce Cellulite Trial Data for 26-Week Period on July 15, 2019”, up 17% as of 9:45am on 267,166 shares traded

CRWD initiated by several analysts today, reports
“Credit Suisse analyst Brad Zelnick started coverage of Crowdstrike with a Neutral rating and $70 price target”

Morgan Stanley’s chief cross-asset strategist Andrew Sheets downgrades global equities, says weaker growth outweighs potential fed dovishness.  Added there is only 1% upside to their price target for major global indices.   “The positives of easier policy will be offset by the negatives of weaker growth,” CNBC reports

1:23pm, SOLY up 52% on 4,677,140 shares traded.  Started breaking out again around 12:30pm

2:19pm, SOLY up 60% now

ROKU slowly creeped up today. 1 percent, 2,percent, 3, now 5 percent closing in on the end of the day. No apparent news.

Dow closes down 115 points

Stay tuned for updates!!

Follow us on twitter!!

Leave a Reply

%d bloggers like this: